---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-161087"
form_type: "8-K"
ticker: "STTK"
cik: "0001680367"
company_name: "Shattuck Labs, Inc."
filed_at: "2024-06-14T23:59:59+00:00"
generated_at: "2026-06-01T04:20:59.980977+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Shattuck Labs reports 67% ORR in HR-MDS, 43% in TP53m AML from SL-172154 Phase 1B

## Summary
- Observed 67% ORR in frontline HR-MDS patients (24 treated), with 42% complete remission rate; median survival not yet reached.
- In 21 frontline TP53m AML patients, ORR 43% with 29% CR; median survival not reached; 5 patients bridged to transplant.
- Manageable safety: no grade 3+ IRRs with dexamethasone premedication; no hemolytic anemia; deaths unrelated to SL-172154.
- Company focusing later-stage development on HR-MDS and TP53m AML; no further PROC development due to competitive landscape.
- Enrollment underway for randomized controlled HR-MDS cohort; regulatory discussions expected later this year.

## SEC filing metadata
- accession: 0001193125-24-161087
- form_type: 8-K
- ticker: STTK
- cik: 0001680367
- company_name: Shattuck Labs, Inc.
- filed_at: 2024-06-14T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1680367/000119312524161087/0001193125-24-161087-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1680367/000119312524161087/d841424d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-161087
- JSON: https://secwatch.observer/filing/0001193125-24-161087.json
- Plain text: https://secwatch.observer/filing/0001193125-24-161087.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.